EUVIMEDEUVIMED entdecken
Crossref

Glucose-6-Phosphate Dehydrogenase is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma

Yiming Niu, Qi Zhu, Jintang Jia

Proceedings of Anticancer Research · 2026

DOI: 10.26689/par.v10i1.13200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of Anticancer Research, 2026. Verfasst von Yiming Niu und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the correlation between the expression of glucose-6-phosphate dehydrogenase (G6PD) and the clinicopathological characteristics, prognosis and immune cell infiltration of hepatocellular carcinoma (HCC).

Methods

The expression of G6PD in liver cancer tissues and normal tissues is extracted from TCGA and GEO databases, validated by immunohistochemistry, and the correlation between G6PD expression and clinical features is analyzed. The clinical significance of G6PD in liver cancer is assessed by Kaplan-Meier, Cox regression, and prognostic line graph models. Functional enrichment analysis is performed by protein-protein interaction (PPI) network, GO/KEGG, GSEA and for G6PD-associated differentially expressed genes (DEGs). TIMER and ssGSEA packages are used to assess the correlation between expression and the level of immune cell infiltration.

Results

Analysis of TCGA and GEO datasets revealed that G6PD expression is significantly upregulated in hepatocellular carcinoma tissues (P < 0.001). G6PD expression is associated with histological grade, pathological stage, T-stage, vascular infiltration, and AFP level (P < 0.05); HCC patients in the low G6PD expression group had longer overall survival and better prognosis compared with the high G6PD expression group (P < 0.05). The level of G6PD expression affects the levels of macrophages, dendritic cells, B cells, and follicular helper T cells in the tumor microenvironment.

Conclusion

High expression of G6PD is a potential biomarker for poor prognosis of hepatocellular carcinoma, and G6PD may be a target for immunotherapy of HCC.

Zitieren

APA

Niu, Y., Zhu, Q., & Jia, J. (2026). Glucose-6-Phosphate Dehydrogenase is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Proceedings of Anticancer Research. https://doi.org/10.26689/par.v10i1.13200

Vancouver

Niu Y, Zhu Q, Jia J. Glucose-6-Phosphate Dehydrogenase is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Proceedings of Anticancer Research. 2026. doi:10.26689/par.v10i1.13200

BibTeX
@article{Niu2026,
  author = {Niu, Yiming and Zhu, Qi and Jia, Jintang},
  title = {Glucose-6-Phosphate Dehydrogenase is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma},
  journal = {Proceedings of Anticancer Research},
  year = {2026},
  doi = {10.26689/par.v10i1.13200}
}
Kostenlos starten →